Using the International Pandemic Instrument to Revitalize the Innovation Ecosystem for Antimicrobial R&D

The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization's (WHO's) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of law, medicine & ethics medicine & ethics, 2022-01, Vol.50 (S2), p.47-54
Main Authors: Caceres, Andrea Morales, Singh, Kshitij Kumar, Minssen, Timo, Van Katwyk, Susan Rogers, Hoffman, Steven J
Format: Article
Language:English
Subjects:
Anti-Infective Agents - therapeutic use
Antimicrobial agents
Coronaviruses
COVID-19
Disadvantaged
Ecosystem
Humans
Intellectual property
International cooperation
Pandemics
Product development
Public health
R&D
Research & development
Symposium
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The inclusion of antimicrobial resistance (AMR) and increased research and development (R&D) capabilities in the most recent outline of the World Health Organization's (WHO's) international pandemic instrument signals an opportunity to reshape pharmaceutical R&D system in favour of antimicrobial product development. This article explains why the current innovation ecosystem has disadvantaged the creation of antimicrobial products for human use. It also highlights how the COVID-19 pandemic experience can inform and stimulate international cooperation to implement innovative R&D incentives to bring new, life-saving antimicrobial products to the market.
ISSN:1073-1105
1748-720X
1748-720X
DOI:10.1017/jme.2022.79